2022 ASTRO Annual Meeting
Jamie Takayesu, MD, on Genitourinary Cancer: Disparity in Physicians’ Assessment of Sexual Dysfunction in Women vs Men
Jamie Takayesu, MD, of the University of Michigan, discusses her findings on how frequently physicians are asking their female and male patients with genitourinary cancers about sexual dysfunction. A...
Alex K. Bryant, MD, on PSA Screening and Metastatic Prostate Cancer in the VA Health-Care System
Alex K. Bryant, MD, of the University of Michigan, examined Veterans Administration (VA) facilities in which lower prostate-specific antigen (PSA) screening rates were associated with a subsequent in...
Emily C. Daugherty, MD, on FLASH Radiotherapy: Efficacy and Safety Results From the First-in-Human Study
Emily C. Daugherty, MD, of the University of Cincinnati, discusses results from the FAST-01 study, which showed that FLASH proton radiotherapy, delivered at ultra-high–dose rates, may be efficacious, ...
Sexual Side Effects of Radiotherapy for Genitourinary Cancers: Is Physician Assessment Equitable for Women and Men?
Many radiation oncologists tend to discuss the sexual side effects of radiation therapy, specifically brachytherapy, with men more often than with women, according to a two-part study reported at the ...
NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carcinoma
Stereotactic body radiation therapy (SBRT) given prior to sorafenib improved overall survival, progression-free survival, and time to disease progression in patients with unresectable advanced hepatoc...
PCS5 Trial: 5 Weeks of Radiation Therapy May Be Equivalent to 8 Weeks in High-Risk Prostate Cancer
According to the results of the phase III randomized Prostate Cancer Study 5 (PCS5), a noninferior trial, 5 weeks of radiation therapy may be equivalent to 8 weeks for men with high-risk prostate canc...
Short Course of Radiotherapy With Concurrent Radiation Boost for High-Risk, Early-Stage Breast Cancer
A 3-week course of radiation therapy including a concomitant boost of radiation to the surgical site appears to be as safe and effective as 4 to 6 weeks of radiation therapy given with a sequential bo...
Randomized Phase II Trial Shows Benefits of Prophylactic Radiation Therapy for Asymptomatic Bone Metastases
The use of prophylactic radiation therapy for patients with metastatic cancer who had asymptomatic, high-risk bone metastases reduced the incidence of skeletal-related events, reduced pain and the num...
Shorter Course of Hypofractionated Radiation Therapy Yields Comparable Results to Conventional Radiotherapy for Patients With Nonmetastatic Soft-Tissue Sarcoma
Patients with nonmetastatic soft-tissue sarcoma who need preoperative radiation therapy can safely receive hypofractionated treatment for 3 weeks instead of 5 weeks, with comparable tumor control and ...
Some Head and Neck Cancer Survivors May Be at Greater Risk for Long-Term Gastrostomy Tube Use
A small subset of patients who have undergone treatment for head and neck cancer may require a gastrostomy tube many years into survivorship, according to a new study published by Galloway et al in th...
Multimodal Artificial Intelligence Models May Offer an Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer
NRG Oncology investigators analyzed clinical and digital histopathology data from five phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multimodal a...
3-Week Course of Radiotherapy With Concurrent Radiation Boost Found to Be Safe and Effective for Patients With Early-Stage Breast Cancer and Elevated Risk of Recurrence
A 3-week course of radiation therapy is as safe and effective as 4 to 6 weeks of treatment for patients with early-stage breast cancer who have a higher risk of having their tumors recur, results of a...
EXTEND Trial: Metastasis-Directed Radiation Therapy Plus Hormone Therapy May Improve Progression-Free Survival in Patients With Advanced Prostate Cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in ...
Response-Adapted Ultra–Low Dose Radiation Achieves Complete Response in Majority of Patients With Orbital Indolent B-Cell Lymphomas
Using a novel response-adapted ultra–low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbita...
Sexual Side Effects of Cancer Treatment Often Unaddressed With Female Patients
A new study has found that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs. ...
Medical Physicist Consults May Help Reduce Patient Anxiety and Increase Satisfaction With Radiation Care
Meeting with a medical physicist who can explain how radiation therapy is planned and delivered may reduce patient anxiety and increase patient satisfaction throughout the treatment process, according...
Prophylactic Radiation for Asymptomatic Bone Metastases May Reduce Pain and Extend Survival
Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple...
PCS5 Trial: Long-Term Outcomes of Moderately Shortened Radiation Course for High-Risk Prostate Cancer
A randomized study has confirmed that patients with high-risk prostate cancer can be treated with 5 vs 8 weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and...
Small First-in-Human Trial Investigates FLASH Proton Radiotherapy for Patients With Bone Metastases
FLASH radiation treatment—which delivers therapeutic doses of radiation in a fraction of a second—may be a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of peo...
Adding SBRT to Sorafenib May Improve Survival and Time to Disease Progression in Patients With Advanced HCC
Adding stereotactic body radiation therapy (SBRT) to systemic therapy with sorafenib for patients with advanced hepatocellular carcinoma (HCC) may extend overall survival and delay tumor progression w...
AI Model Using Daily Step Counts May Help Predict Unplanned Hospitalizations During Cancer Therapy
An artificial intelligence (AI) model developed by researchers may assist in predicting the likelihood that a patient may have an unplanned hospitalization during radiation treatments for cancer. The ...
